Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or e‑Newsletters.
In this trial, treatment with apremilast showed significantly greater improvement in American College of Rheumatology 20% (ACR20) improvement response criteria and Health Assessment Questionnaire Disability Index (HAQ-DI) scores at week 16 for 20- and 30-mg twice-daily doses compared with placebo (Wells AF, et al. Rheumatology. 2018 Apr 4. Epub ahead of print).
Read Now